1.
Sharifnia T, Rusu V, Piccioni F, et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014;111(52):18661-6. doi:10.1073/pnas.1412228112.
1.
Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6(6):e20351. doi:10.1371/journal.pone.0020351.
1.
Giltnane JM, Hutchinson KE, Stricker TP, et al. Genomic profiling of ER breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9(402). doi:10.1126/scitranslmed.aai7993.
1.
Golfmann K, Meder L, Koker M, et al. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018;37(42):5682-5693. doi:10.1038/s41388-018-0380-3.
1.
Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008;68(3):664-73. doi:10.1158/0008-5472.CAN-07-2615.
1.
Tan L, Wang J, Tanizaki J, et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A. 2014;111(45):E4869-77. doi:10.1073/pnas.1403438111.